Lv12
30 积分 2023-03-27 加入
ENSIFENTRINE, A NOVEL DUAL PHOSPHODIESTERASE (PDE) 3 AND 4 INHIBITOR, PROVIDES EFFECTIVE BRONCHODILATION WHEN ADMINISTERED BY METERED DOSE INHALER IN PATIENTS WITH COPD
13小时前
已完结
Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, provides effective bronchodilation when administered by dry powder inhaler in COPD
13小时前
已关闭
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials
16小时前
已完结
Idiopathic inflammatory myopathies related lung disease in adults
3个月前
已完结
Duration and Frequency of Spirometry Needed to Accurately Reflect Annualized Change of FEV1 in COPD
4个月前
已完结
Neuropsychiatric diagnoses after montelukast initiation in paediatric patients with asthma
5个月前
已关闭
Cost-related nonadherence to medication among people with asthma in the United States: findings that reinforce the relevance of history and healthcare reform
5个月前
已关闭
Impact of day-to-day variation in FEV1 on measures of change: A conceptual description
5个月前
已完结
Can We Use Lung Function Thresholds and Respiratory Symptoms to Identify Pre-COPD? A Prospective, Population-based Cohort Study
6个月前
已完结
Eosinophils, mucus plugs, and clinical outcomes: Findings from two COPD cohorts
6个月前
已关闭
皖公网安备34019202002308
